“…If it is assumed that ac-hydroxylation is a primary step in the activation of all nitrosamines it should follow that analogues having partially or fully blocked os-positions will be non-carcinogenic, and this is broadly observed. Diphenylnitrosamine is noncarcinogenic in several species (Hashida et al, 1973;Innes et al, 1969), t-butyl ethylnitrosamine (63) is both non-carcinogenic (Druckrey et al, 1963) and nonmutagenic (Pasternak, 1963) and the piperidine derivative (64) is of very low or zero carcinogenicity (Lijinsky and Taylor, 1975) (Buglass et al, 1974;Welzel, 1971) and in some (Johnston et al, 1975) Druckrey, 1975;Ward and Weisburger, 1975), and several derivatives are employed as antitumour agents (Wheeler, 1975;Reed and May, 1975 (70) suggested that the carcinogenicity of both cycasin and dimethylnitrosamine may be expressed via a common alkylating intermediate Matsumoto and Higa, 1966), and this has been made more likely by the synthesis of the dimethylnitrosamine intermediate (62), which happens to be isomeric with the cycasin ester (69). Likewise, a similarity between the acute liver toxicity produced by both dimethylnitrosamine and elaiomycin (70) has been noted (Schoental, 1967).…”